Alzheimer disease: Current therapy and future therapeutic strategies

Alzheimer Disease and Associated Disorders

Volumn 14, Issue SUPPL. 1, 2000, Pages

  Hirai, Shunsaku ^a  

^a TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

Author keywords

Alzheimer disease; Antidementia drugs; Future therapeutic strategies

Indexed keywords

1 (BENZO[B]THIEN 5 YL) 2 (2 DIETHYLAMINOETHOXY)ETHANOL; 2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; ACETYLCARNITINE; ACETYLCHOLINESTERASE; CEREBROLYSIN; CERULETIDE; CHOLECYSTOKININ OCTAPEPTIDE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CORTICOTROPIN; DONEPEZIL; EBIRATIDE; ESTERASE INHIBITOR; INDOMETACIN; MUSCARINIC AGENT; N BENZYL 2 [[2 (HYDROXYACETYL) 1 PYRROLIDINYL]CARBONYL] 1 PYRROLIDINECARBOXAMIDE; NEFIRACETAM; NERVE GROWTH FACTOR; NEUROPEPTIDE; NICOTINIC AGENT; NOOTROPIC AGENT; OCTREOTIDE; PROTIRELIN; RIVASTIGMINE; SOMATOSTATIN; TACRINE; TALTIRELIN; UNINDEXED DRUG; VASOPRESSIN; ZANEPEZIL;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DISEASE COURSE; FUTUROLOGY; HUMAN; LICENSING; META ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG DESIGN; FORECASTING; HUMANS;

EID: 0034082561     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200000001-00003     Document Type: Conference Paper

References (13)

1. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease. Am J Psychiatry 1994;115:1105-13.
2. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999;281: 1401-6.
3. McGeer PL, Rogers J, McGeer EC. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 1994;8: 149-58.
4. McLachlan CDR. Aluminum and Alzheimer's disease. Neurobiol Aging 1986;7:525-32.
5. McLachlan CDR, Dalton AJ, Kruck TPA, et al. Desferrioxamine for Alzheimer's disease. Lancet 1991;338:324-6.
6. Olson L, Nordberg A, von Holst H, et al. Nerve growth factor affects C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient [case report]. J Neural Transm 1992;4:79-95.
7. Rogers J, Cooper NR, Webster S, et al. Complement activation by β amyloid in Alzheimer's disease. Proc Nat Acad Sci U S A 1992;89: 10016-20.
8. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
9. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marccusson J, Karlsson I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement Geriatr Cog Disord 1998;9(suppl 1):36-43.
10. Schultz J, Schaller J, McKinley M, et al. Enhanced cytotoxicity of amyloid β peptide by a complement dependent mechanism. Neurosci Lett 1994;175:99-102.
11. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
12. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:4766-70.
13. Weyer G, Erzigkeit H, Hadler D, Kubicki S. Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: a double blind, placebo controlled multicentre study. Human Psychopharmacol 1996;11:53-65.